NeoGenomics (FRA:NG9) Cyclically Adjusted PS Ratio: (As of Sep. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:NG9 NeoGenomics Inc FRA:NG9
72 GF Score
Price €17.15
GF Value €13.97
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is NeoGenomics Cyclically Adjusted PS Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


NeoGenomics  (FRA:NG9) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


NeoGenomics Cyclically Adjusted PS Ratio Related Terms


NeoGenomics Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for NeoGenomics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NeoGenomics Cyclically Adjusted PS Ratio Chart

NeoGenomics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.28 2.92 4.50 4.16 2.46

NeoGenomics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.49 1.54 2.44 1.44 2.78

FRA:NG9 vs WGS, CDNA, PSNL: Cyclically Adjusted PS Ratio Comparison

For the Diagnostics & Research subindustry, NeoGenomics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NeoGenomics Cyclically Adjusted PS Ratio vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, NeoGenomics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where NeoGenomics's Cyclically Adjusted PS Ratio falls into.


FRA:NG9
72GF Score
NeoGenomics Inc FRA:NG9
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

NeoGenomics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

NeoGenomics's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, NeoGenomics's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.326/333.9520*333.9520
=1.326

Current CPI (Jun. 2026) = 333.9520.

NeoGenomics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.697 241.428 0.964
201612 0.715 241.432 0.989
201703 0.685 243.801 0.938
201706 0.712 244.955 0.971
201709 0.633 246.819 0.856
201712 0.648 246.524 0.878
201803 0.641 249.554 0.858
201806 0.631 251.989 0.836
201809 0.654 252.439 0.865
201812 0.692 251.233 0.920
201903 0.888 254.202 1.167
201906 0.885 256.143 1.154
201909 0.873 256.759 1.135
201912 0.895 256.974 1.163
202003 0.921 258.115 1.192
202006 0.732 257.797 0.948
202009 0.972 260.280 1.247
202012 0.925 260.474 1.186
202103 0.825 264.877 1.040
202106 0.770 271.696 0.946
202109 0.840 274.310 1.023
202112 0.894 278.802 1.071
202203 0.845 287.504 0.982
202206 0.946 296.311 1.066
202209 1.028 296.808 1.157
202212 1.091 296.797 1.228
202303 1.023 301.836 1.132
202306 1.077 305.109 1.179
202309 1.111 307.789 1.205
202312 1.149 306.746 1.251
202403 1.141 312.332 1.220
202406 1.209 314.175 1.285
202409 1.203 315.301 1.274
202412 1.268 315.605 1.342
202503 1.253 319.799 1.308
202506 1.250 322.561 1.294
202509 1.251 324.800 1.286
202512 1.270 324.054 1.309
202603 1.235 330.213 1.249
202606 1.326 333.952 1.326

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is NeoGenomics (FRA:NG9) Overvalued in 2026?

Based on GuruFocus' analysis, NeoGenomics stock appears to be overvalued. The current stock price of €17.15 is trading 22.7% above its estimated GF Value™ of €13.97. GuruFocus considers NeoGenomics to be Modestly Overvalued.

Key valuation signals for FRA:NG9:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €13.97 vs. price of €17.15 (22.7% above fair value)
  • GF Score™: 72/100 with 6 warning signs

No single metric tells the full story. See the FRA:NG9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


NeoGenomics Business Description

Other Exchanges NEO:USANEO:Mexico
Address 9490 NeoGenomics Way, Fort Myers, FL, USA, 33912
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
72GF Score

Get the complete analysis for FRA:NG9

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€17.15
Price
€13.97
GF Value